{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:00:50Z","timestamp":1761948050450},"reference-count":121,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,5]],"date-time":"2014-05-05T00:00:00Z","timestamp":1399248000000},"content-version":"vor","delay-in-days":1342,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1593\/neo.10610","type":"journal-article","created":{"date-parts":[[2015,4,23]],"date-time":"2015-04-23T12:58:20Z","timestamp":1429793900000},"page":"685-696","source":"Crossref","is-referenced-by-count":40,"title":["Evolving Role of Bone Biomarkers in Castration-Resistant Prostate Cancer"],"prefix":"10.1016","volume":"12","author":[{"given":"Janet E.","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheryl","family":"Sim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1593\/neo.10610_bib1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/annonc\/mdl498","article-title":"Estimates of the cancer incidence and mortality in Europe in 2006","volume":"18","author":"Ferlay","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1593\/neo.10610_bib2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1593\/neo.10610_bib3","doi-asserted-by":"crossref","first-page":"vii91","DOI":"10.1093\/annonc\/mdn473","article-title":"Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer","volume":"19","author":"Sternberg","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1593\/neo.10610_bib4","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1593\/neo.10610_bib5","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients","volume":"31","author":"Bubendorf","year":"2000","journal-title":"Hum Pathol"},{"key":"10.1593\/neo.10610_bib6","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/cncr.10788","article-title":"Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival","volume":"95","author":"Cheville","year":"2002","journal-title":"Cancer"},{"key":"10.1593\/neo.10610_bib7","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdq037","article-title":"Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer","author":"Rajpar","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1593\/neo.10610_bib8","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1002\/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.0.CO;2-Q","article-title":"The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma","volume":"88","author":"Carlin","year":"2000","journal-title":"Cancer"},{"key":"10.1593\/neo.10610_bib9","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1158\/1535-7163.MCT-07-0234","article-title":"Molecular biology of bone metastasis","volume":"6","author":"Kingsley","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1593\/neo.10610_bib10","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1593\/neo.10610_bib11","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.1210\/jc.2003-030910","article-title":"Clinical review 165: markers of bone remodeling in metastatic bone disease","volume":"88","author":"Fohr","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1593\/neo.10610_bib12","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1593\/neo.10610_bib13","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/ncponc0320","article-title":"Clinical use of markers of bone turnover in metastatic bone disease","volume":"2","author":"Seibel","year":"2005","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1593\/neo.10610_bib14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.1593\/neo.10610_bib15","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","volume":"16","author":"Weinfurt","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1593\/neo.10610_bib16","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"10.1593\/neo.10610_bib17","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3816\/CGC.2007.n.022","article-title":"Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases","volume":"5","author":"Saad","year":"2007","journal-title":"Clin Genitourin Cancer"},{"key":"10.1593\/neo.10610_bib18","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3816\/SCT.2005.n.017","article-title":"Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic acid in patients with bone metastases from solid tumors","volume":"2","author":"Major","year":"2005","journal-title":"Support Cancer Ther"},{"key":"10.1593\/neo.10610_bib19","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1200\/JCO.2007.13.4536","article-title":"American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer","volume":"25","author":"Basch","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1593\/neo.10610_bib20","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1593\/neo.10610_bib21","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1593\/neo.10610_bib22","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"key":"10.1593\/neo.10610_bib23","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1593\/neo.10610_bib24","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone- refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1593\/neo.10610_bib25","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cncr.22504","article-title":"The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid","volume":"109","author":"Oh","year":"2007","journal-title":"Cancer"},{"key":"10.1593\/neo.10610_bib26","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/02841860500341173","article-title":"Jaw complications in breast and prostate cancer patients treated with zoledronic acid","volume":"45","author":"Ortega","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1593\/neo.10610_bib27","article-title":"Denosumab-related osteonecrosis of the jaws","author":"Kyrgidis","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1593\/neo.10610_bib28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(07)70147-X","article-title":"Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study","volume":"8","author":"Nilsson","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1593\/neo.10610_bib29","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2008.18.9811","article-title":"Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castrationresistant prostate cancer","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1593\/neo.10610_bib30","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.2008.20.4164","article-title":"Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer","volume":"27","author":"Morris","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1593\/neo.10610_bib31","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1200\/JCO.1998.16.5.1835","article-title":"Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormonerefractory prostate cancer","volume":"16","author":"Smith","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1593\/neo.10610_bib32","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2007.11.4769","article-title":"Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer","volume":"25","author":"Armstrong","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1593\/neo.10610_bib33","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1200\/JCO.2008.19.9810","article-title":"Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group trials 9346 (intergroup study 0162) and 9916","volume":"27","author":"Hussain","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1593\/neo.10610_bib34","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Schroder","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1593\/neo.10610_bib35","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.eururo.2005.06.009","article-title":"Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project","volume":"48","author":"van Gils","year":"2005","journal-title":"Eur Urol"},{"key":"10.1593\/neo.10610_bib36","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/MOU.0b013e3282fb7807","article-title":"Clinical endpoints for drug development in prostate cancer","volume":"18","author":"Ramiah","year":"2008","journal-title":"Curr Opin Urol"},{"key":"10.1593\/neo.10610_bib37","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/1078-0432.CCR-07-1355","article-title":"A phase II clinical trial of sorafenib in androgen-independent prostate cancer","volume":"14","author":"Dahut","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1593\/neo.10610_bib38","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/annonc\/mdp111","article-title":"Phase II study of sunitinib in men with advanced prostate cancer","volume":"20","author":"Dror Michaelson","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1593\/neo.10610_bib39","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ctrv.2008.05.001","article-title":"Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions","volume":"34","author":"Coleman","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1593\/neo.10610_bib40","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/clinchem\/36.7.1328","article-title":"Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen","volume":"36","author":"Melkko","year":"1990","journal-title":"Clin Chem"},{"key":"10.1593\/neo.10610_bib41","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/clinchem\/42.6.947","article-title":"Immunoassay for intact amino-terminal propeptide of human type I procollagen","volume":"42","author":"Melkko","year":"1996","journal-title":"Clin Chem"},{"key":"10.1593\/neo.10610_bib42","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/8756-3282(96)00165-2","article-title":"Procollagen type I N-terminal propeptide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval, and hypovitaminosis D induced hyperparathyroidism","volume":"19","author":"Orum","year":"1996","journal-title":"Bone"},{"key":"10.1593\/neo.10610_bib43","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/clinchem\/41.11.1560","article-title":"Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum","volume":"41","author":"Gomez","year":"1995","journal-title":"Clin Chem"},{"key":"10.1593\/neo.10610_bib44","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1093\/clinchem\/42.11.1796","article-title":"Comparison of total and bonespecific alkaline phosphatase in patients with nonskeletal disorder or metabolic bone diseases","volume":"42","author":"Woitge","year":"1996","journal-title":"Clin Chem"},{"key":"10.1593\/neo.10610_bib45","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/000456320003700402","article-title":"Measurement of osteocalcin","volume":"37","author":"Lee","year":"2000","journal-title":"Ann Clin Biochem"},{"key":"10.1593\/neo.10610_bib46","first-page":"461","article-title":"Assessment of urinary pyridinoline excretion with a specific enzyme-linked immunosorbent assay in normal adults and in metabolic bone diseases","volume":"16","author":"Arbault","year":"1995","journal-title":"Bone"},{"key":"10.1593\/neo.10610_bib47","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0003-2697(03)00241-0","article-title":"High-performance liquid chromatography method to analyze free and total urinary pyridinoline and deoxypyridinoline","volume":"318","author":"Vesper","year":"2003","journal-title":"Anal Biochem"},{"key":"10.1593\/neo.10610_bib48","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/jbmr.5650091019","article-title":"Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption","volume":"9","author":"Robins","year":"1994","journal-title":"J Bone Miner Res"},{"key":"10.1593\/neo.10610_bib49","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1093\/clinchem\/40.11.2022","article-title":"Immunoassay for quantifying type I collagen degradation products in urine evaluated","volume":"40","author":"Bonde","year":"1994","journal-title":"Clin Chem"},{"key":"10.1593\/neo.10610_bib50","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/clinchem\/42.10.1639","article-title":"Coated-tube radioimmunoassay for C-telopeptides of type I collagen to assess bone resorption","volume":"42","author":"Bonde","year":"1996","journal-title":"Clin Chem"},{"key":"10.1593\/neo.10610_bib51","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s002239900497","article-title":"Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment","volume":"63","author":"Gertz","year":"1998","journal-title":"Calcif Tissue Int"},{"key":"10.1593\/neo.10610_bib52","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/jbmr.5650071119","article-title":"A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine","volume":"7","author":"Hanson","year":"1992","journal-title":"J Bone Miner Res"},{"key":"10.1593\/neo.10610_bib53","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/clinchem\/39.4.635","article-title":"Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation","volume":"39","author":"Risteli","year":"1993","journal-title":"Clin Chem"},{"key":"10.1593\/neo.10610_bib54","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1093\/clinchem\/43.11.2076","article-title":"Improved purification of human bone sialoprotein and development of a homologous radioimmunoassay","volume":"43","author":"Karmatschek","year":"1997","journal-title":"Clin Chem"},{"key":"10.1593\/neo.10610_bib55","first-page":"4060","article-title":"Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer","volume":"7","author":"Fedarko","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1593\/neo.10610_bib56","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/clinchem\/47.4.747","article-title":"ELISA methodology for detection of modified osteoprotegerin in clinical studies","volume":"47","author":"Chen","year":"2001","journal-title":"Clin Chem"},{"key":"10.1593\/neo.10610_bib57","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1210\/jcem-71-2-442","article-title":"Development of an immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase","volume":"71","author":"Kraenzlin","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1593\/neo.10610_bib58","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/clinchem\/33.4.458","article-title":"Characterization and assay of tartrate-resistant acid phosphatase activity in serum: potential use to assess bone resorption","volume":"33","author":"Lau","year":"1987","journal-title":"Clin Chem"},{"key":"10.1593\/neo.10610_bib59","first-page":"5517","article-title":"Aggressive breast cancer leads to discrepant serum levels of the type I procollagen propeptides PINP and PICP","volume":"57","author":"Jukkola","year":"1997","journal-title":"Cancer Res"},{"key":"10.1593\/neo.10610_bib60","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1046\/j.1464-410x.2001.00105.x","article-title":"The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone","volume":"87","author":"Koizumi","year":"2001","journal-title":"BJU Int"},{"key":"10.1593\/neo.10610_bib61","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1742-1241.2008.01911.x","article-title":"Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club","volume":"63","author":"Bergmann","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1593\/neo.10610_bib62","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/cncr.21978","article-title":"Expression of RANKL\/RANK\/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation","volume":"107","author":"Chen","year":"2006","journal-title":"Cancer"},{"key":"10.1593\/neo.10610_bib63","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/02841860600635870","article-title":"Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-\u03baB ligand (RANKL)\/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton","volume":"46","author":"Mountzios","year":"2007","journal-title":"Acta Oncol"},{"key":"10.1593\/neo.10610_bib64","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1007\/s001980070003","article-title":"Molecular markers of bone turnover: biochemical, technical and analytical aspects","volume":"11","author":"Seibel","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1593\/neo.10610_bib65","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1359\/jbmr.2003.18.5.859","article-title":"The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation","volume":"18","author":"Garnero","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1593\/neo.10610_bib66","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF02555854","article-title":"Expression of bone sialoprotein (BSP) in developing human tissues","volume":"49","author":"Bianco","year":"1991","journal-title":"Calcif Tissue Int"},{"key":"10.1593\/neo.10610_bib67","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/jnci\/90.13.1000","article-title":"Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer","volume":"90","author":"Waltregny","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1593\/neo.10610_bib68","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/clinchem\/47.3.597","article-title":"Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption","volume":"47","author":"Halleen","year":"2001","journal-title":"Clin Chem"},{"key":"10.1593\/neo.10610_bib69","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/ctrv.2000.0213","article-title":"Markers of bone turnover in prostate cancer","volume":"27","author":"Garnero","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.1593\/neo.10610_bib70","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1054\/bjoc.1999.1012","article-title":"Markers of bone turnover for the management of patients with bone metastases from prostate cancer","volume":"82","author":"Garnero","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1593\/neo.10610_bib71","first-page":"671","article-title":"Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma","volume":"29","author":"Klepzig","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1593\/neo.10610_bib72","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.juro.2007.05.029","article-title":"Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach","volume":"178","author":"Koopmans","year":"2007","journal-title":"J Urol"},{"key":"10.1593\/neo.10610_bib73","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/1055-9965.EPI-05-0492","article-title":"The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients","volume":"15","author":"Leeming","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1593\/neo.10610_bib74","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/ijc.20314","article-title":"Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications","volume":"111","author":"Jung","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1593\/neo.10610_bib75","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1593\/neo.10610_bib76","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1593\/neo.10610_bib77","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1158\/1078-0432.CCR-06-0269","article-title":"Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer","volume":"12","author":"Cook","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1593\/neo.10610_bib78","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/pros.20311","article-title":"Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma","volume":"66","author":"Brasso","year":"2006","journal-title":"Prostate"},{"key":"10.1593\/neo.10610_bib79","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1158\/1078-0432.CCR-06-2616","article-title":"Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival","volume":"13","author":"Johansen","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1593\/neo.10610_bib80","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"10.1593\/neo.10610_bib81","first-page":"1457","article-title":"Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid","volume":"25","author":"Pectasides","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1593\/neo.10610_bib82","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.eururo.2007.02.033","article-title":"Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression","volume":"52","author":"Lein","year":"2007","journal-title":"Eur Urol"},{"key":"10.1593\/neo.10610_bib83","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/pros.20917","article-title":"Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid","volume":"69","author":"Lein","year":"2009","journal-title":"Prostate"},{"key":"10.1593\/neo.10610_bib84","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1200\/JCO.2003.04.176","article-title":"Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial","volume":"21","author":"Carducci","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1593\/neo.10610_bib85","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/01.ju.0000042162.08938.27","article-title":"Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan","volume":"169","author":"Nelson","year":"2003","journal-title":"J Urol"},{"key":"10.1593\/neo.10610_bib86","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/cncr.22996","article-title":"A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormonerefractory prostate cancer","volume":"110","author":"Carducci","year":"2007","journal-title":"Cancer"},{"key":"10.1593\/neo.10610_bib87","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/cncr.22043","article-title":"Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer","volume":"107","author":"Michaelson","year":"2006","journal-title":"Cancer"},{"key":"10.1593\/neo.10610_bib88","doi-asserted-by":"crossref","first-page":"6270","DOI":"10.1158\/1078-0432.CCR-08-1085","article-title":"A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer","volume":"14","author":"Armstrong","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1593\/neo.10610_bib89","article-title":"A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer","author":"Schelman","year":"2009","journal-title":"Invest New Drugs"},{"key":"10.1593\/neo.10610_bib90","doi-asserted-by":"crossref","first-page":"7421","DOI":"10.1158\/1078-0432.CCR-09-1691","article-title":"Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer","volume":"15","author":"Yu","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1593\/neo.10610_bib91","doi-asserted-by":"crossref","first-page":"270s","DOI":"10.1200\/jco.2009.27.15_suppl.5147","article-title":"A phase II study of once-daily dasatinib for patients with castration-resistant prostate cancer (CA180085)","volume":"27","author":"Yu","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1593\/neo.10610_bib92","doi-asserted-by":"crossref","first-page":"415S","DOI":"10.1016\/S1359-6349(09)71406-5","article-title":"Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer (CRPC): analysis of study CA180-086","volume":"7","author":"Araujo","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1593\/neo.10610_bib93","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1359\/jbmr.090830","article-title":"Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple ascending dose phase I trial","volume":"25","author":"Hannon","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1593\/neo.10610_bib94","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/CAD.0b013e328325a867","article-title":"A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study","volume":"20","author":"Lara","year":"2009","journal-title":"Anticancer Drugs"},{"key":"10.1593\/neo.10610_bib95","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1359\/jbmr.090810","article-title":"Effects of denosumab in patients with bone metastases, with and without previous bisphosphonate exposure","volume":"25","author":"Body","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1593\/neo.10610_bib96","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1593\/neo.10610_bib97","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.juro.2009.04.023","article-title":"Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial","volume":"182","author":"Fizazi","year":"2009","journal-title":"J Urol"},{"key":"10.1593\/neo.10610_bib98","series-title":"Denosumab demonstrated superiority over zometa in pivotal phase 3 head-to-head trial in prostate cancer patients with bone metastases","year":"2010"},{"key":"10.1593\/neo.10610_bib99","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/leu.2008.237","article-title":"Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor","volume":"23","author":"Brownlow","year":"2009","journal-title":"Leukemia"},{"key":"10.1593\/neo.10610_bib100","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6- methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"10.1593\/neo.10610_bib101","doi-asserted-by":"crossref","first-page":"9185","DOI":"10.1158\/0008-5472.CAN-05-1731","article-title":"Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells","volume":"65","author":"Nam","year":"2005","journal-title":"Cancer Res"},{"key":"10.1593\/neo.10610_bib102","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1158\/0008-5472.CAN-07-2997","article-title":"Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model","volume":"68","author":"Park","year":"2008","journal-title":"Cancer Res"},{"key":"10.1593\/neo.10610_bib103","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/leu.2008.356","article-title":"Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis","volume":"23","author":"Vandyke","year":"2009","journal-title":"Leukemia"},{"key":"10.1593\/neo.10610_bib104","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1158\/1541-7786.MCR-08-0219","article-title":"The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts","volume":"7","author":"de Vries","year":"2009","journal-title":"Mol Cancer Res"},{"key":"10.1593\/neo.10610_bib105","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1158\/0008-5472.CAN-08-0442","article-title":"Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer","volume":"69","author":"Yang","year":"2009","journal-title":"Cancer Res"},{"key":"10.1593\/neo.10610_bib106","doi-asserted-by":"crossref","first-page":"10954","DOI":"10.1073\/pnas.1830978100","article-title":"A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases","volume":"100","author":"Yin","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1593\/neo.10610_bib107","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/cncr.11129","article-title":"Role of endothelin-1 in osteoblastic bone metastases","volume":"97","author":"Guise","year":"2003","journal-title":"Cancer"},{"key":"10.1593\/neo.10610_bib108","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.eururo.2008.11.002","article-title":"Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebocontrolled, randomised, phase 2 trial","volume":"55","author":"James","year":"2009","journal-title":"Eur Urol"},{"key":"10.1593\/neo.10610_bib109","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/clinchem\/45.8.1359","article-title":"Clinical utility of biochemical markers of bone remodeling","volume":"45","author":"Watts","year":"1999","journal-title":"Clin Chem"},{"key":"10.1593\/neo.10610_bib110","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1586\/14789450.2.5.693","article-title":"Cancer proteomics: many technologies, one goal","volume":"2","author":"Conrads","year":"2005","journal-title":"Expert Rev Proteomics"},{"key":"10.1593\/neo.10610_bib111","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1002\/pmic.200401275","article-title":"A novel four-dimensional strategy combining protein and peptide separation methods enables detection of low-abundance proteins in human plasma and serum proteomes","volume":"5","author":"Tang","year":"2005","journal-title":"Proteomics"},{"key":"10.1593\/neo.10610_bib112","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1586\/14789450.4.3.371","article-title":"Proteomic analysis of bone cancer: a review of current and future developments","volume":"4","author":"Bhattacharyya","year":"2007","journal-title":"Expert Rev Proteomics"},{"key":"10.1593\/neo.10610_bib113","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3233\/CBM-2006-2603","article-title":"Surface-enhanced laser desorption\/ionization time-of-flight mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer","volume":"2","author":"Kohli","year":"2006","journal-title":"Cancer Biomark"},{"key":"10.1593\/neo.10610_bib114","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1373\/clinchem.2004.041087","article-title":"Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions","volume":"51","author":"Le","year":"2005","journal-title":"Clin Chem"},{"key":"10.1593\/neo.10610_bib115","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1155\/2006\/728296","article-title":"Biomarkers that discriminate multiple myeloma patients with or without skeletal involvement detected using SELDI-TOF mass spectrometry and statistical and machine learning tools","volume":"22","author":"Bhattacharyya","year":"2006","journal-title":"Dis Markers"},{"key":"10.1593\/neo.10610_bib116","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.1158\/1078-0432.CCR-07-1506","article-title":"Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer","volume":"13","author":"Danila","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1593\/neo.10610_bib117","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1373\/clinchem.2008.117952","article-title":"Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with Cell Search assay and association with bone metastases and with survival","volume":"55","author":"Helo","year":"2009","journal-title":"Clin Chem"},{"key":"10.1593\/neo.10610_bib118","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castrationresistant prostate cancer","volume":"14","author":"de Bono","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1593\/neo.10610_bib119","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1470-2045(08)70340-1","article-title":"Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data","volume":"10","author":"Scher","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1593\/neo.10610_bib120","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1634\/theoncologist.2009-0043","article-title":"Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature","volume":"14","author":"Armstrong","year":"2009","journal-title":"Oncologist"},{"key":"10.1593\/neo.10610_bib121","doi-asserted-by":"crossref","first-page":"6213s","DOI":"10.1158\/1078-0432.CCR-06-1007","article-title":"Basic mechanisms responsible for osteolytic and osteoblastic bone metastases","volume":"12","author":"Guise","year":"2006","journal-title":"Clin Cancer Res"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558610800703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558610800703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T07:12:53Z","timestamp":1598944373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558610800703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":121,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S1476558610800703"],"URL":"https:\/\/doi.org\/10.1593\/neo.10610","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}